EUVIMEDEUVIMED entdecken
Crossref

Assessment of Temporary Warfarin Reversal in Patients With Left Ventricular Assist Devices: the KVAD Study*

Katelyn W Sylvester, Jessica Grandoni, Megan Rhoten, Lara Coakley, Erin Lyons-Matiello, Katie Frankel, Brooke Fortin, Kate Jolley, Hae Soo Park, Revital Y Freedman, Mandeep R Mehra, Michael M Givertz und 1 weitere

Journal of Cardiac Failure · 2024

DOI: 10.1016/j.cardfail.2024.02.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2024. Verfasst von Katelyn W Sylvester und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA. Electronic address: https://twitter.com/KatelynSylvester4. Hauptthemen laut MEDLINE: Warfarin, Heart-Assist Devices, Anticoagulants, Blood Coagulation Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: CSL Behring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with left ventricular assist devices (LVADs) require interruption of warfarin for invasive procedures, but parenteral bridging is associated with many complications. Four-factor prothrombin complex concentrate (4F-PCC) can temporarily restore hemostasis in patients undergoing anticoagulation with warfarin. OBJECTIVES: This pilot study evaluated the strategy of using variable-dose 4F-PCC to immediately and temporarily reverse warfarin before invasive procedures without holding warfarin in patients with LVADs. The duration of effect of 4F-PCC on factor levels and time to reestablish therapeutic anticoagulation post procedure were assessed. METHODS: Adult patients with LVADs and planned invasive procedures were enrolled from a single center. Warfarin was continued uninterrupted. The 4F-PCC dose administered immediately pre-procedure was based on study protocol. International normalized ratio (INR)- and vitamin K-dependent factor levels were collected before and during the 48 hours after 4F-PCC administration. The use of parenteral bridging, International Society for Thrombosis and Haemostasis major and clinically relevant nonmajor bleeding (CRNMB) and thromboembolic events at 7 and 30 days were collected. RESULTS: In 21 episodes of 4F-PCC reversal, median baseline INR was 2.7 (IQR 2.2-3.2). The median dosage of 4F-PCC administered was 1794 units (IQR 1536-2130). At 24 and 48 hours post 4F-PCC administration, median INRs were 1.8 (IQR 1.7-2.0) and 2.0 (IQR 1.9-2.4). Two patients required postoperative bridging. One patient experienced major bleeding within 72 hours, and 2 experienced CRNMB within 30 days. There were no thromboembolic events. Baseline and post 4F-PCC vitamin K-dependent factor levels corresponded with changes in INR values. The median time to achieve therapeutic INR post-procedure was 2.5 days (IQR, 1-4). CONCLUSION: Administration of 4F-PCC for temporary reversal of warfarin for invasive procedures in patients with LVADs allowed for continued warfarin dosing with minimal use of post-intervention bridging, limited bleeding and no thromboembolic events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WarfarinHeart-Assist DevicesAnticoagulantsBlood Coagulation FactorsInternational Normalized RatioHumansFemaleMaleMiddle AgedPilot ProjectsAgedHeart FailureProspective StudiesThromboembolismAdult

Stichwörter der Autor:innen

LVADWarfarinperiprocedural managementreversal

Substanzen

WarfarinAnticoagulantsprothrombin complex concentratesBlood Coagulation Factors

Autor:innen und Institutionen

  • Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA. Electronic address: https://twitter.com/KatelynSylvester4.
  • Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.
  • Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA.
  • Division of Hematology, Brigham and Women's Hospital, Boston, MA.
  • Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA. Electronic address: https://twitter.com/MRMehraMD.
  • Center for Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA. Electronic address: https://twitter.com/GivertzMichael.

Förderung

  • CSL Behring

Zitieren

APA

Sylvester, K. W., Grandoni, J., Rhoten, M., Coakley, L., Lyons-Matiello, E., Frankel, K., Fortin, B., Jolley, K., Park, H. S., Freedman, R. Y., Mehra, M. R., Givertz, M. M., & Connors, J. M. (2024). Assessment of Temporary Warfarin Reversal in Patients With Left Ventricular Assist Devices: the KVAD Study*. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2024.02.022

Vancouver

Sylvester KW, Grandoni J, Rhoten M, Coakley L, Lyons-Matiello E, Frankel K, et al. Assessment of Temporary Warfarin Reversal in Patients With Left Ventricular Assist Devices: the KVAD Study*. Journal of Cardiac Failure. 2024. doi:10.1016/j.cardfail.2024.02.022

BibTeX
@article{Sylvester2024,
  author = {Sylvester, Katelyn W and Grandoni, Jessica and Rhoten, Megan and Coakley, Lara and Lyons-Matiello, Erin and Frankel, Katie and Fortin, Brooke and Jolley, Kate and Park, Hae Soo and Freedman, Revital Y and Mehra, Mandeep R and Givertz, Michael M and Connors, Jean M},
  title = {Assessment of Temporary Warfarin Reversal in Patients With Left Ventricular Assist Devices: the KVAD Study*},
  journal = {Journal of Cardiac Failure},
  year = {2024},
  doi = {10.1016/j.cardfail.2024.02.022}
}
Kostenlos starten →